Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated

Advanced Risk Stratification: Understanding Your Outlook

At a Glance

Doctors use the FLIPI and FLIPI-2 scoring systems to predict how your follicular lymphoma will behave based on clinical factors and blood tests. Remaining progression-free for 24 months after treatment (POD24) is a key positive milestone, while early relapse may require different therapies.

When you are first diagnosed with follicular lymphoma (FL), your medical team uses several “scoring systems” to help predict how the disease might behave and how you might respond to treatment. These scores don’t just look at the cancer; they look at your body’s reaction to it and the specific genetic “blueprint” of the cells [1][2].

Prognostic Scoring Systems

The most common way doctors stratify risk is by using the FLIPI (Follicular Lymphoma International Prognostic Index) and its newer version, FLIPI-2 [2][1].

FLIPI vs. FLIPI-2

The original FLIPI was designed before many modern treatments (like rituximab) were standard. FLIPI-2 was created to be more accurate for patients receiving today’s therapies [1][3].

Variable FLIPI Factors [2] FLIPI-2 Factors [2]
Age Over 60 years Over 60 years
Stage Stage III or IV Bone marrow involvement
Blood Work Hemoglobin < 120 g/L Hemoglobin < 120 g/L
Enzymes/Proteins Elevated LDH (Lactate Dehydrogenase) Elevated Beta-2 Microglobulin
Nodes/Size More than 4 nodal areas Largest node > 6 cm

Risk Groups:

  • Low Risk (0-1 factors): Very high survival rates; many people stay in remission for a decade or more [2][1].
  • Intermediate Risk (2 factors): A middle ground where treatment is usually very effective [3][4].
  • High Risk (3+ factors): The disease may be more active and might require closer monitoring or more intensive initial treatment [2][3].

m7-FLIPI: The Genetic Layer

The m7-FLIPI is a “clinicogenetic” model. It combines the clinical factors above with the mutation status of seven specific genes (such as EZH2, CREBBP, and KMT2D) [5][2]. This score is particularly good at identifying patients who might not respond as well to standard chemotherapy [5][6].

The 24-Month Milestone (POD24)

One of the most important concepts in follicular lymphoma today is POD24, which stands for Progression of Disease within 24 months of starting your first treatment [7][8].

  • Why it matters: Most people (about 80%) with FL do not experience a relapse within the first two years of therapy. For those who do (POD24), the disease is considered “high-risk” [9][10].
  • Outlook: While reaching the 24-month mark without progression is a very positive sign, experiencing POD24 suggests the lymphoma may be more aggressive, and your doctor may consider different treatments, such as stem cell transplantation or CAR-T cell therapy, sooner than they otherwise would [11][12].

Histologic Transformation (HT)

In a small number of cases—about 2% to 3% each year—follicular lymphoma can “transform” into a faster-growing, more aggressive type of cancer, usually Diffuse Large B-cell Lymphoma (DLBCL) [13][14][15]. However, this risk plateaus over time, meaning your overall cumulative lifetime risk of transformation is typically around 15-20%, rather than continually stacking up [14].

The Mechanism: Transformation happens when the slow-growing FL cells acquire “high-risk” genetic errors, such as a rearrangement of the MYC gene or a mutation in the TP53 tumor suppressor gene [16][17]. Think of it like the cancer cells “upgrading” their engine to move much faster [18].

What to Watch For: Transformation often causes a sudden, rapid change in how you feel, such as:

  • A single lymph node growing very quickly while others stay the same.
  • A sudden return of drenching night sweats or unexplained weight loss.
  • New, intense pain in a specific area of the body.

If transformation is suspected, your doctor will likely perform a new biopsy to confirm the change and pivot to a more aggressive treatment plan [19][20].

Common questions in this guide

What is a FLIPI score in follicular lymphoma?
The Follicular Lymphoma International Prognostic Index (FLIPI) is a scoring system doctors use to predict how your disease might behave. It evaluates factors like your age, disease stage, blood work, and the size of your lymph nodes to categorize your risk level.
What does POD24 mean and why is it important?
POD24 stands for progression of disease within 24 months of starting your first treatment. If your disease does not progress during this time, it is a very positive sign. If it does progress early, it suggests the lymphoma is more aggressive and may require therapies like stem cell transplantation or CAR-T cell therapy.
Can follicular lymphoma turn into a more aggressive cancer?
Yes, in about 2% to 3% of cases each year, it can transform into a faster-growing cancer, usually Diffuse Large B-cell Lymphoma (DLBCL). Signs of transformation include sudden, rapid growth of a single lymph node, new intense pain, or a return of drenching night sweats.
What is the m7-FLIPI score?
The m7-FLIPI is a newer scoring model that combines standard clinical risk factors with the genetic mutation profile of your cancer cells. It looks at specific genes like EZH2 and TP53 to identify patients who might need a different approach than standard chemotherapy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific FLIPI or FLIPI-2 score, and which risk category does it place me in?
  2. 2.Was a m7-FLIPI or other clinicogenetic score calculated using my biopsy's mutation profile?
  3. 3.Based on my risk score, what is the likelihood that I might experience POD24 (progression within 24 months)?
  4. 4.What specific signs should I look for that might suggest my lymphoma is 'transforming' into a more aggressive type?
  5. 5.If I do experience early progression, what are our options for second-line therapy or clinical trials?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    [Prognostic study of 229 follicular lymphoma patients treated with rituximab combined with chemotherapy].

    Wang N, Xu PP, Wang L, et al.

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2019; (40(1)):46-51 doi:10.3760/cma.j.issn.0253-2727.2019.01.009.

    PMID: 30704228
  2. 2

    Prognostication of Follicular Lymphoma: A Review of Prognostic Scores and Factors.

    Jóna Á, Kiss E, Illés Á

    Diagnostics (Basel, Switzerland) 2025; (15(5)) doi:10.3390/diagnostics15050647.

    PMID: 40075894
  3. 3

    Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.

    Maeng CH, Ahn SW, Ryu SY, et al.

    The Korean journal of internal medicine 2016; (31(3)):560-9 doi:10.3904/kjim.2014.222.

    PMID: 26898595
  4. 4

    [Prognostic Significance of Follicular Lymphoma International Prognostic Index 2 (FLIPI2) in Follicular Lymphoma Patients Treated with Rituximab Maintenance].

    Xu PP, Qian Y, Chen QS, et al.

    Zhongguo shi yan xue ye xue za zhi 2017; (25(2)):426-430 doi:10.7534/j.issn.1009-2137.2017.02.021.

    PMID: 28446287
  5. 5

    Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

    Pastore A, Jurinovic V, Kridel R, et al.

    The Lancet. Oncology 2015; (16(9)):1111-1122 doi:10.1016/S1470-2045(15)00169-2.

    PMID: 26256760
  6. 6

    Follicular Lymphoma: Diagnostic and Prognostic Considerations in Initial Treatment Approach.

    Boughan KM, Caimi PF

    Current oncology reports 2019; (21(7)):63 doi:10.1007/s11912-019-0808-0.

    PMID: 31119485
  7. 7

    Divergent paths: management of early relapsed follicular lymphoma.

    Takiar R, Karimi Y, Phillips TJ

    Hematology. American Society of Hematology. Education Program 2022; (2022(1)):666-675 doi:10.1182/hematology.2022000360.

    PMID: 36485106
  8. 8

    Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy.

    Jurinovic V, Kridel R, Staiger AM, et al.

    Blood 2016; (128(8)):1112-20 doi:10.1182/blood-2016-05-717355.

    PMID: 27418643
  9. 9

    Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcome.

    Bitansky G, Avigdor A, Vasilev E, et al.

    Leukemia & lymphoma 2020; (61(11)):2645-2651 doi:10.1080/10428194.2020.1786554.

    PMID: 32643497
  10. 10

    Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma: Real-World Report of Polish Lymphoma Research Group.

    Paszkiewicz-Kozik E, Debowska M, Jakacka N, et al.

    Chemotherapy 2022; (67(4)):201-210 doi:10.1159/000523921.

    PMID: 35249035
  11. 11

    Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.

    Freeman CL, Kridel R, Moccia AA, et al.

    Blood 2019; (134(9)):761-764 doi:10.1182/blood.2019000258.

    PMID: 31300404
  12. 12

    Survival Outcomes of Patients with Follicular Lymphoma after Relapse or Progression: A Single-Center Real-World Data Analysis.

    Lee YP, Lee MS, Yoon SE, et al.

    Journal of oncology 2022; (2022()):2263217 doi:10.1155/2022/2263217.

    PMID: 36199784
  13. 13

    Transformed follicular lymphoma.

    Fischer T, Zing NPC, Chiattone CS, et al.

    Annals of hematology 2018; (97(1)):17-29 doi:10.1007/s00277-017-3151-2.

    PMID: 29043381
  14. 14

    Managing Follicular Lymphoma in the Elderly Population.

    Tan JJC, Sze YL, Choong Shi Hui C

    Case reports in medicine 2023; (2023()):1038934 doi:10.1155/2023/1038934.

    PMID: 36643720
  15. 15

    [Transformation of Follicular Lymphoma into Composite Lymphoma: A Case Report and Literature Review].

    Avilés-Salas A, Peña-Carvajalino LF, Heredia-Jara AN, et al.

    Revista medica de Chile 2024; (152(4)):508-513 doi:10.4067/s0034-98872024000400508.

    PMID: 39450819
  16. 16

    Transformed lymphoma: what should I do now?

    Smith S

    Hematology. American Society of Hematology. Education Program 2020; (2020(1)):306-311 doi:10.1182/hematology.2020000115.

    PMID: 33275671
  17. 17

    High-grade B-Cell lymphoma with MYC and BCL6 rearrangements associated with Richter transformation of chronic lymphocytic leukemia.

    Rogers TS, Gardner JA, Devitt KA

    Autopsy & case reports 2019; (9(3)):e2019090 doi:10.4322/acr.2019.090.

    PMID: 31440479
  18. 18

    miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels.

    Musilova K, Devan J, Cerna K, et al.

    Blood 2018; (132(22)):2389-2400 doi:10.1182/blood-2018-06-855502.

    PMID: 30213873
  19. 19

    Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era.

    Arushi Khurana , Mwangi R, Ansell SM, et al.

    Blood cancer journal 2021; (11(7)):133 doi:10.1038/s41408-021-00525-0.

    PMID: 34274939
  20. 20

    A man in his forties with increasing shortness of breath.

    Tveiten H, Lehne G, Aukrust P, et al.

    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 2020; (140(6)) doi:10.4045/tidsskr.19.0692.

    PMID: 32321231

This page explains follicular lymphoma risk scoring and prognostic milestones for educational purposes only. Always discuss your individual FLIPI score, genetic testing results, and treatment outlook with your oncologist.

Get notified when new evidence is published on Follicular lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.